IRON
MCID: IRN002
MIFTS: 57

Iron Metabolism Disease (IRON)

Categories: Blood diseases, Metabolic diseases, Respiratory diseases

Aliases & Classifications for Iron Metabolism Disease

MalaCards integrated aliases for Iron Metabolism Disease:

Name: Iron Metabolism Disease 12 15
Iron Deficiency 74 54 71 32
Iron Metabolism Disorders 43 71
Iron Disorder 12 54
Disorder of Iron Metabolism 12
Iron 42

Classifications:



External Ids:

Disease Ontology 12 DOID:2351
ICD9CM 34 275.0
MeSH 43 D019189
SNOMED-CT 67 30913008
UMLS 71 C0012715 C0240066

Summaries for Iron Metabolism Disease

MedlinePlus : 42 Iron is a mineral that our bodies need for many functions. For example, iron is part of hemoglobin, a protein which carries oxygen from our lungs throughout our bodies. It helps our muscles store and use oxygen. Iron is also part of many other proteins and enzymes. Your body needs the right amount of iron. If you have too little iron, you may develop iron deficiency anemia. Causes of low iron levels include blood loss, poor diet, or an inability to absorb enough iron from foods. People at higher risk of having too little iron are young children and women who are pregnant or have periods. Too much iron can damage your body. Taking too many iron supplements can cause iron poisoning. Some people have an inherited disease called hemochromatosis. It causes too much iron to build up in the body. Centers for Disease Control and Prevention

MalaCards based summary : Iron Metabolism Disease, also known as iron deficiency, is related to neurodegeneration with brain iron accumulation 3 and congenital dyserythropoietic anemia. An important gene associated with Iron Metabolism Disease is HFE (Homeostatic Iron Regulator), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Glucose / Energy Metabolism. The drugs Edoxaban and Apixaban have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are hematopoietic system and cardiovascular system

Wikipedia : 74 Iron deficiency, or sideropaenia, is the state in which a body lacks enough iron to supply its needs.... more...

Related Diseases for Iron Metabolism Disease

Diseases related to Iron Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1979)
# Related Disease Score Top Affiliating Genes
1 neurodegeneration with brain iron accumulation 3 33.7 SLC11A2 IREB2 FTL CP ACO1
2 congenital dyserythropoietic anemia 32.6 TFRC HFE HAMP EPO
3 hemochromatosis, type 2b 32.0 HAMP FTL
4 hemochromatosis, type 5 32.0 TFR2 IREB2 HJV HFE FTL ACO1
5 restless legs syndrome 31.9 TFRC SLC11A2 IREB2 FTL EPO ACO1
6 atransferrinemia 31.7 TFRC TFR2 TF SLC40A1 SLC11A2 HJV
7 hemochromatosis, type 3 31.7 TFRC TFR2 SLC40A1 HJV HFE HAMP
8 hemochromatosis, type 2a 31.6 TFR2 SLC40A1 HJV HFE HAMP
9 hemochromatosis, type 4 31.4 TFR2 SLC40A1 SLC11A2 HJV HFE HEPH
10 iron overload in africa 30.9 TFR2 TF SLC40A1 HJV HFE HAMP
11 iron-refractory iron deficiency anemia 30.6 HJV EPO
12 arthropathy 30.5 HJV HFE HAMP CRP
13 end stage renal failure 30.5 TF EPO CRP CP
14 sickle cell disease 30.5 HBB HBA2 EPO
15 sickle cell anemia 30.3 HBB HBA2 EPO
16 eales disease 30.2 TF CP
17 hyperferritinemia with or without cataract 30.2 TF HFE FTL
18 erythrocytosis, familial, 2 30.1 EPO CYBRD1 ACO1
19 folic acid deficiency anemia 30.0 EPO CRP
20 wilson disease 30.0 TFRC SLC11A2 HFE CP
21 red cell aplasia 29.9 TF EPO
22 alpha-thalassemia 29.9 TFRC HFE HBB HBA2 EPO
23 anemia of prematurity 29.9 HAMP EPO
24 acquired polycythemia 29.9 HAMP EPO
25 protoporphyria, erythropoietic, 1 29.9 TFRC IREB2 ACO1
26 polycythemia 29.8 TFRC HBB HBA2 HAMP EPO
27 erythroleukemia, familial 29.8 HBB EPO
28 analbuminemia 29.8 TF EPO CRP
29 neonatal anemia 29.8 HBA2 EPO
30 viral hepatitis 29.7 HFE CRP CP
31 splenic sequestration 29.7 HBB EPO
32 nutritional deficiency disease 29.7 TFRC TF SLC11A2 HJV HAMP EPO
33 anemia, sideroblastic, 1 29.7 TFRC TFR2 SLC40A1 SLC11A2 IREB2 HJV
34 hydrops fetalis, nonimmune 29.7 HBB HBA2
35 brucellosis 29.7 SLC11A1 HAMP CRP
36 chronic kidney disease 29.6 TF HAMP EPO CRP
37 hemochromatosis type 2 29.6 TFRC TFR2 SLC40A1 SLC11A2 HJV HFE
38 hypochromic microcytic anemia 29.6 TF SLC11A2 HJV HBB HBA2 HAMP
39 visceral leishmaniasis 29.4 SLC11A1 HAMP CRP
40 beta-thalassemia 29.3 TFRC TFR2 TF HJV HFE HBB
41 heinz body anemias 29.3 HBB HBA2
42 aceruloplasminemia 29.2 TFRC TFR2 SLC40A1 SLC11A2 IREB2 HJV
43 hemoglobinopathy 29.1 TFRC TFR2 TF HJV HFE HBB
44 extrapulmonary tuberculosis 29.1 SLC11A1 HAMP CRP
45 hemosiderosis 29.0 TFRC TFR2 TF SLC40A1 SLC11A2 IREB2
46 friedreich ataxia 29.0 TFRC SLC40A1 SLC11A2 IREB2 HFE HAMP
47 hemolytic anemia 29.0 TFRC TF HBB HBA2 EPO
48 sideroblastic anemia 29.0 TFRC TFR2 SLC40A1 IREB2 HJV HFE
49 hemochromatosis, type 1 29.0 TFRC TFR2 TF SLC40A1 SLC11A2 MT-CYB
50 buruli ulcer 28.9 SLC11A1 HBB

Comorbidity relations with Iron Metabolism Disease via Phenotypic Disease Network (PDN):


Deficiency Anemia Pulmonary Hemosiderosis

Graphical network of the top 20 diseases related to Iron Metabolism Disease:



Diseases related to Iron Metabolism Disease

Symptoms & Phenotypes for Iron Metabolism Disease

MGI Mouse Phenotypes related to Iron Metabolism Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 CP EPO HEPH HFE HJV IREB2
2 cardiovascular system MP:0005385 10.02 CP CRP CYBRD1 EPO HEPH HJV
3 homeostasis/metabolism MP:0005376 10 ACO1 CP CRP CYBRD1 EPO HEPH
4 immune system MP:0005387 9.77 CP CRP EPO HEPH HFE HJV
5 liver/biliary system MP:0005370 9.36 CP CYBRD1 EPO HEPH HFE HJV

Drugs & Therapeutics for Iron Metabolism Disease

Drugs for Iron Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 656)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Edoxaban Approved Phase 4 480449-70-5
2
Apixaban Approved Phase 4 503612-47-3 10182969
3
Rivaroxaban Approved Phase 4 366789-02-8
4
Nevirapine Approved Phase 4 129618-40-2 4463
5
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
6
Lumefantrine Approved Phase 4 82186-77-4 6437380
7
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
8
Artemether Approved Phase 4 71963-77-4 119380 68911
9
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
10
Halofantrine Approved Phase 4 69756-53-2 37393
11
Ferrous gluconate Approved Phase 4 299-29-6
12
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
13
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
14
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
15
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
16
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
17
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
18
Topiramate Approved Phase 4 97240-79-4 5284627
19
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
20
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
21
Ribavirin Approved Phase 4 36791-04-5 37542
22
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
23
Somatostatin Approved, Investigational Phase 4 51110-01-1, 38916-34-6 53481605
24
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
25
Atorvastatin Approved Phase 4 134523-00-5 60823
26
Ledipasvir Approved Phase 4 1256388-51-8 67505836
27
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
28
Pravastatin Approved Phase 4 81093-37-0 54687
29
lanreotide Approved Phase 4 108736-35-2
30
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
31
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
32
Ferric maltol Approved Phase 4 33725-54-1
33
Metformin Approved Phase 4 657-24-9 14219 4091
34
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
35
Iodine Approved, Investigational Phase 4 7553-56-2 807
36
Copper Approved, Investigational Phase 4 7440-50-8 27099
37
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
38
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
39
Ferrous fumarate Approved Phase 4 141-01-5
40
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
41
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2, 11096-26-7
42
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
43
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
44
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
45
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
46
Taurine Approved, Nutraceutical Phase 4 107-35-7 1123
47
Choline Approved, Nutraceutical Phase 4 62-49-7 305
48
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
49
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
50
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960

Interventional clinical trials:

(show top 50) (show all 2251)
# Name Status NCT ID Phase Drugs
1 The Effect of a Nutrient Fortified Oat Drink on Iron, Zinc, Vitamin A, and Vitamin C Status Among Filipino Children Unknown status NCT01418898 Phase 4
2 Randomized, Controlled Study of Iron Supplementation of Infants With Birth Weights 2000-2500 g Unknown status NCT00558454 Phase 4 Iron
3 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
4 A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting Unknown status NCT01950247 Phase 4 Injectafer;SOC
5 Effectiveness of Iron Supplementation in the Second Year of Life for Prevention of Iron Deficiency Unknown status NCT00479102 Phase 4 Ferripel-3 - iron polysaccharide complex for prevention
6 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
7 Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations. Unknown status NCT00248716 Phase 4 Ferrous gluconate and iron polysaccharide complex
8 Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension Unknown status NCT01288651 Phase 4 Ferricarboxymaltose
9 Effektivität Der in Der Schwangerschaftsvorsorge routinemässig Angewandten Eisenprophylaxe Unknown status NCT02487719 Phase 4 Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia
10 Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance In Non Anemic Premenopausal Women With Low Ferritin Levels Unknown status NCT01374776 Phase 4 Double blind, randomized, placebo controlled inter
11 Double-Blind, Single-Center Interventional Trial To Evaluate The Effect Of Intravenous Iron Versus Placebo On Cerebral Dopamine Receptor Density In Non Anaemic Premenopausal Women With Low Ferritin Levels And Fatigue Unknown status NCT03305705 Phase 4 Iron Carboxymaltose;Sodium chloride 0.9%
12 A Randomized, Double-blind, Multi-center Clinical Trial Prospectively Evaluating Iron Protein Succinylate Oral Solution in Treating Patients With Chronic Heart Failure and Iron Deficiency Unknown status NCT03344523 Phase 4 Iron protein succinylate oral solution
13 Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass Unknown status NCT02086968 Phase 4 Injectafer;Ferrous Sulfate tablets
14 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
15 Iron Absorption Trial Unknown status NCT02228902 Phase 4 Ferrous fumarate;Ferrous gluconate
16 Combination With Intravenous Iron Supplementation or Doubling Erythropoietin Dose for Patients With Chemotherapy-induced Anaemia Inadequately Responsive to Initial Erythropoietin Treatment Alone Unknown status NCT02731378 Phase 4 Erythropoietins (EPO);Aggressive iron dextran supplementation;Erythropoietins (EPO);Sustained iron dextran supplementation
17 Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial. Unknown status NCT02242188 Phase 4 Iron
18 The Impact of Treatment of Anaemia With Intravenous Iron on Haematological Values for Patients After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
19 Supplementation With Lactoferrin in Preterm Newborns Unknown status NCT01172236 Phase 4 Lactoferrin;Lactoferrin
20 Effects of Early Short-term Intravenous Iron Supplements Combinded EPO in Preterm Infants Unknown status NCT02060851 Phase 4 Iron sucrose;EPO
21 Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia Unknown status NCT01084122 Phase 4 Iron sucrose
22 A Multi-Center, Open-Label, Randomized, Parallel Group Study of the Efficacy and Safety of Ferrlecit in the Maintenance of Iron Stores and Serum Hemoglobin Concentration in Hemodialysis Patients Receiving Erythropoietin. Unknown status NCT00223938 Phase 4 Oral Iron;sodium ferric gluconate;sodium ferric gluconate
23 The Value of Iron Treatment for Postoperative Patients With Anemia: a Randomized Double Blind Controlled Trial Unknown status NCT01975272 Phase 4 Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
24 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
25 Predictors of Response to Treatment With Iron and Erythropoietin in Dialysis Anaemia Unknown status NCT02707757 Phase 4 Iron sucrose;Erythopoietin stimulating agent
26 A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance Unknown status NCT00103753 Phase 4 deferiprone
27 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
28 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
29 Does Intraoperative Intravenous Iron Sucrose Enhance Postoperative Oxygenation Profile in Total Arthroplasty Surgery? Unknown status NCT02544828 Phase 4 Iron Sucrose 200mg;placebo
30 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
31 A Comparison Between Two Different Oral Appliance Therapies: Somnodent vs Herbst Appliance in Patients With Mild and Moderate OSA Unknown status NCT02724865 Phase 4
32 The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis Unknown status NCT02661295 Phase 4 Ferric Citrate
33 The Effect of Intra Venus Ferric Carboxymaltose Preoperative on Hemoglobin and Blood Transfusion Post Cardiac Surgery Unknown status NCT02939794 Phase 4 Ferinject;Placebo
34 Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation Unknown status NCT02935855 Phase 4 Dabigatran;Apixaban;Rivaroxaban;Edoxaban;Warfarin;Acenocumarole
35 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
36 Sienna+® Injection Time Study: A Prospective Multicentre, Controlled Clinical Trial to Evaluate the Performance of Superparamagnetic Iron Oxide vs. Standard Technique as Tracer in Sentinel Node Biopsy Unknown status NCT02612870 Phase 4
37 An Open-labeled Pilot Study to Determine the Efficacy of an E2//Nomegestrol Acetate (E2/NOMAC)Combination Oral Contraceptive (COC) in the Management of Heavy Menstrual Bleeding (HMB) Unknown status NCT01715025 Phase 4 E2Nomac
38 Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study. Unknown status NCT00331656 Phase 4
39 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
40 Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients Unknown status NCT01128101 Phase 4 Spironolactone
41 Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
42 Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau. Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
43 Prevention of Iron Deficiency in Breastfed Infants Completed NCT01444261 Phase 4
44 The Effect of Lactoferrin Versus Iron Supplement in Treating Iron Deficiency Anemia and Helping Weight Loss in Obese School Age Children Completed NCT04014855 Phase 4 Iron Supplement
45 Dialysis Patients' Response to IV Iron With Elevated Ferritin Completed NCT00224081 Phase 4 Sodium ferric gluconate,
46 Randomized Double-Blind Parallel Group MultiCenter Study of the Efficacy of Two Doses of Ferrlecit® in Treatment of Iron Deficiency in Pediatric Hemodialysis Patients Receiving Epoetin. Completed NCT00223964 Phase 4 Ferrlecit (sodium ferric gluconate complex in sucrose injection)
47 A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency Completed NCT01453608 Phase 4 Ferinject (ferric carboxymaltose);Placebo (saline)
48 A Prospective, Randomized, Multi-centered Trial to Compare the Efficacy and Safety of Intravenous Iron Sucrose (Venoferrum®) With Oral Iron Acetyl-transferrin Hydroglycerin (Bolgre®) in Pregnant Women With Iron Deficiency Anemia Completed NCT00802139 Phase 4 venoferrum(iron sucrose);Bolgre (Iron acetyl-transferase)
49 A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease Completed NCT00224055 Phase 4 Sodium Ferric Gluconate Complex in Sucrose Injection;Ferrous sulfate tablets
50 A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease Being Treated With Erythropoietic Therapy Completed NCT00224042 Phase 4 Sodium Ferric Gluconate complex in sucrose;Ferrous sulfate tablets

Search NIH Clinical Center for Iron Metabolism Disease

Cochrane evidence based reviews: iron metabolism disorders

Genetic Tests for Iron Metabolism Disease

Anatomical Context for Iron Metabolism Disease

MalaCards organs/tissues related to Iron Metabolism Disease:

40
Kidney, Heart, Liver, Brain, Testes, Bone, Breast

Publications for Iron Metabolism Disease

Articles related to Iron Metabolism Disease:

(show top 50) (show all 19203)
# Title Authors PMID Year
1
Duplicate portion sampling gives the most accurate iron intake estimate: Implications for iron status of female students. 61 42
30982441 2018
2
Association between dietary iron intake and the prevalence of nonalcoholic fatty liver disease: A cross-sectional study. 42
31651873 2019
3
The use of folic acid, iron salts and other vitamins by pregnant women in the 2015 Pelotas birth cohort: is there socioeconomic inequality? 42
31277638 2019
4
Elevated soluble transferrin receptor levels reflect increased erythropoietic drive rather than iron deficiency in pediatric sickle cell disease. 54 61
20486179 2010
5
Alpha 1-acid glycoprotein, hepcidin, C-reactive protein, and serum ferritin are correlated in anemic schoolchildren with Schistosoma haematobium. 54 61
20410090 2010
6
Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency. 54 61
19624802 2010
7
Posttransplant anemia in solid organ recipients. 54 61
20303457 2010
8
Ceramide in suicidal death of erythrocytes. 54 61
20502001 2010
9
The role of transferrin receptor 1 and 2 in transferrin-bound iron uptake in human hepatoma cells. 54 61
19828835 2009
10
Ferric carboxymaltose in patients with heart failure and iron deficiency. 54 61
19920054 2009
11
[Soluble tranferrin receptor in the biological diagnosis of iron deficiency. Report of 24 cases]. 54 61
20209848 2009
12
Iron stores, periodic leg movements, and sleepiness in obstructive sleep apnea. 54 61
20465018 2009
13
Impact of socioeconomic and health related factors on the iron status of adolescent girls from two boarding schools in Southern Benin. 54 61
20306766 2009
14
[Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)]. 54 61
20232547 2009
15
Differential ferritin expression is associated with iron deficiency in coeliac disease. 54 61
19404207 2009
16
Transferrin and ferritin response to bacterial infection: the role of the liver and brain in fish. 54 61
19428486 2009
17
Influence of inflammation as measured by alpha-1-acid glycoprotein on iron status indicators among HIV-positive postpartum Zimbabwean women. 54 61
18506200 2009
18
Pediatric reference intervals for soluble transferrin receptor and transferrin receptor-ferritin index. 54 61
19718534 2009
19
Evaluation of iron deficiency as a nutritional adaptation to infectious disease: an evolutionary medicine perspective. 54 61
18949769 2009
20
Abnormal brain iron homeostasis in human and animal prion disorders. 54 61
19283067 2009
21
Early effects on T lymphocyte response to iron deficiency in mice. Short communication. 54 61
18825318 2009
22
Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. 54 61
19147412 2009
23
[Immune, inflammatory, and nutritional protein profile in children with iron deficiency in Côte d'Ivoire]. 54 61
19801348 2009
24
Differing expression of genes involved in non-transferrin iron transport across plasma membrane in various cell types under iron deficiency and excess. 54 61
18830567 2009
25
The soluble transferrin receptor (TfR)-F-Index is not applicable as a test for iron status in patients with chronic lymphocytic leukemia. 54 61
19743956 2009
26
Suicide for survival--death of infected erythrocytes as a host mechanism to survive malaria. 54 61
19710527 2009
27
Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. 54 61
18987297 2009
28
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. 54 61
18815282 2009
29
Parenteral ascorbic acid in haemodialysis patients. 54 61
18827578 2008
30
Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia. 54 61
18974579 2008
31
Erythrocyte programmed cell death. 54 61
18720418 2008
32
Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. 54 61
18469314 2008
33
[Old and new iron parameters in iron metabolism and diagnostics]. 54 61
18791966 2008
34
Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. 54 61
18613854 2008
35
Iron-independent phosphorylation of iron regulatory protein 2 regulates ferritin during the cell cycle. 54 61
18574241 2008
36
Soluble transferrin receptor and sTfR-F index for assessing concurrent iron deficiency in patients with chronic renal failure. 54 61
18317758 2008
37
[Expression of iron regulatory protein-2 and ferritins in intestinal mucosa of rats with iron deficiency]. 54 61
18549630 2008
38
Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment. 54 61
18174266 2008
39
Reticulocyte haemoglobin content vs. soluble transferrin receptor and ferritin index in iron deficiency anaemia accompanied with inflammation. 54 61
18279424 2008
40
Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. 54 61
18029550 2008
41
Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics, and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. 54 61
18201677 2008
42
Prognostic value of reticulocyte hemoglobin content to diagnose iron deficiency in 6-24-month-old children. 54 61
18971604 2008
43
Potential roles of erythropoietin in the management of anaemia and other complications diabetes. 54 61
17645562 2008
44
Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. 54 61
18212498 2008
45
Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. 54 61
18094727 2008
46
Effect of erythropoietin on hepcidin, DMT1 with IRE, and hephaestin gene expression in duodenum of rats. 54 61
18306987 2008
47
The relationship between iron deficiency anemia and lipid metabolism in premenopausal women. 54 61
18004086 2007
48
Iron deficiency and NRAMP1 polymorphisms (INT4, D543N and 3'UTR) do not contribute to severity of anaemia in tuberculosis in the Indonesian population. 54 61
17466092 2007
49
Molecular genetic studies of DMT1 on 12q in French-Canadian restless legs syndrome patients and families. 54 61
17510944 2007
50
Inflammation and iron deficiency in the hypoferremia of obesity. 54 61
17438557 2007

Variations for Iron Metabolism Disease

Expression for Iron Metabolism Disease

Search GEO for disease gene expression data for Iron Metabolism Disease.

Pathways for Iron Metabolism Disease

Pathways related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.21 TFRC TF SLC40A1 SLC11A2 SLC11A1 HEPH
2 12.34 SLC11A2 IREB2 HBB CP ACO1
3
Show member pathways
12.06 TFRC TF SLC40A1 SLC11A2 SLC11A1 HEPH
4 11.71 TFRC TF EPO
5
Show member pathways
11.7 SLC40A1 SLC11A2 SLC11A1 HEPH CP
6
Show member pathways
11.67 HBB HBA2 FTL
7 11.52 TFRC TF EPO CP
8 11.5 TF SLC40A1 SLC11A2 HEPH FTL CYBRD1
9 11.23 TFRC TF SLC40A1 SLC11A2 FTL CP
10 10.39 HJV HFE HAMP
11 10.3 TFRC TFR2 TF SLC40A1 SLC11A2 IREB2

GO Terms for Iron Metabolism Disease

Cellular components related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.11 TFRC TF HBB HBA2 HAMP FTL
2 extracellular space GO:0005615 10.02 TFRC TF HJV HFE HBB HBA2
3 cell surface GO:0009986 9.92 TFRC TF SLC11A2 HJV EPO
4 early endosome GO:0005769 9.8 TFRC TF SLC11A2 HFE
5 endosome membrane GO:0010008 9.71 TFRC TF SLC11A2 SLC11A1
6 recycling endosome GO:0055037 9.67 TFRC TF SLC11A2 HFE
7 blood microparticle GO:0072562 9.55 TFRC TF HBB HBA2 CP
8 endocytic vesicle lumen GO:0071682 9.51 HBB HBA2
9 cell GO:0005623 9.5 TFRC TFR2 TF SLC40A1 SLC11A2 SLC11A1
10 hemoglobin complex GO:0005833 9.48 HBB HBA2
11 haptoglobin-hemoglobin complex GO:0031838 9.43 HBB HBA2
12 basal part of cell GO:0045178 9.43 TF SLC11A2 HFE
13 HFE-transferrin receptor complex GO:1990712 9.35 TFRC TFR2 TF HJV HFE

Biological processes related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 10.04 TF SLC40A1 SLC11A2 SLC11A1 HFE HEPH
2 receptor-mediated endocytosis GO:0006898 9.87 TFRC TFR2 HBB HBA2
3 iron ion transport GO:0006826 9.85 TFRC TFR2 TF SLC40A1 SLC11A2 SLC11A1
4 acute-phase response GO:0006953 9.8 TFR2 HFE HAMP EPO CRP
5 transferrin transport GO:0033572 9.73 TFRC TFR2 TF HFE
6 response to iron ion GO:0010039 9.72 TFR2 SLC11A2 HFE HAMP CYBRD1
7 osteoclast differentiation GO:0030316 9.71 TFRC TF IREB2
8 iron ion homeostasis GO:0055072 9.7 TFR2 TF SLC40A1 SLC11A2 SLC11A1 IREB2
9 iron ion transmembrane transport GO:0034755 9.67 TF SLC40A1 SLC11A2 SLC11A1
10 copper ion transport GO:0006825 9.65 SLC11A2 HEPH CP
11 multicellular organismal iron ion homeostasis GO:0060586 9.65 SLC40A1 SLC11A2 SLC11A1 HFE HAMP
12 cellular response to iron ion GO:0071281 9.63 TFR2 TF HFE
13 positive regulation of bone resorption GO:0045780 9.62 TFRC TF
14 oxygen transport GO:0015671 9.61 HBB HBA2
15 response to hyperoxia GO:0055093 9.61 MT-CYB EPO
16 intestinal absorption GO:0050892 9.6 IREB2 ACO1
17 manganese ion transport GO:0006828 9.59 SLC11A2 SLC11A1
18 positive regulation of peptide hormone secretion GO:0090277 9.58 TFR2 HFE
19 manganese ion transmembrane transport GO:0071421 9.58 SLC11A2 SLC11A1
20 citrate metabolic process GO:0006101 9.56 IREB2 ACO1
21 cadmium ion transmembrane transport GO:0070574 9.55 SLC11A2 SLC11A1
22 response to iron ion starvation GO:1990641 9.52 HFE HAMP
23 regulation of iron ion transport GO:0034756 9.51 TF HFE
24 cellular iron ion homeostasis GO:0006879 9.5 TFRC TFR2 TF SLC40A1 SLC11A2 SLC11A1

Molecular functions related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 10.28 TF MT-CYB IREB2 HEPH HBB HBA2
2 metal ion transmembrane transporter activity GO:0046873 9.58 SLC11A2 SLC11A1
3 oxygen carrier activity GO:0005344 9.58 HBB HBA2
4 co-receptor binding GO:0039706 9.57 TFR2 HFE
5 ferric iron binding GO:0008199 9.56 TF FTL
6 organic acid binding GO:0043177 9.55 HBB HBA2
7 haptoglobin binding GO:0031720 9.52 HBB HBA2
8 ferrous iron transmembrane transporter activity GO:0015093 9.51 SLC40A1 SLC11A2
9 manganese ion transmembrane transporter activity GO:0005384 9.49 SLC11A2 SLC11A1
10 aconitate hydratase activity GO:0003994 9.48 IREB2 ACO1
11 transition metal ion transmembrane transporter activity GO:0046915 9.46 SLC11A2 SLC11A1
12 transferrin transmembrane transporter activity GO:0033570 9.43 TFRC TFR2
13 ferrous iron binding GO:0008198 9.43 TF HEPH FTL
14 iron-responsive element binding GO:0030350 9.4 IREB2 ACO1
15 cadmium ion transmembrane transporter activity GO:0015086 9.37 SLC11A2 SLC11A1
16 ferroxidase activity GO:0004322 9.33 HEPH FTL CP
17 transferrin receptor activity GO:0004998 9.32 TFRC TFR2
18 transferrin receptor binding GO:1990459 9.13 TF HJV HFE
19 iron ion transmembrane transporter activity GO:0005381 8.8 SLC40A1 SLC11A2 SLC11A1

Sources for Iron Metabolism Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....